zuranolone

zuranolone
IUPAC name	(3S,3aR,7S,7aR)-3-(2,4-difluorophenyl)-2-oxo-3,3a,4,5,6,7-hexahydro-2H-indazole-7-carboxamide
Tradename	Zurzuvae
CAS number	1632051-40-1
DrugBank	DB16118
UNII	1H8T5Y1M7M
Synonyms	SAGE-217

zuranolone. Zuranolone, marketed under the brand name Zurzuvae, is a neuroactive steroid and a positive allosteric modulator of the GABAA receptor. It was developed by Sage Therapeutics and Biogen and received approval from the U.S. Food and Drug Administration in August 2023 for the treatment of postpartum depression in adults. This oral medication represents a significant advancement as the first FDA-approved oral treatment specifically indicated for this condition, offering a novel mechanism of action distinct from traditional antidepressants.

Medical uses

Zuranolone is indicated for the treatment of postpartum depression in adults, as approved by the U.S. Food and Drug Administration. Its use is specifically for a short-term treatment course, typically administered over a 14-day period. The approval was based on data from clinical programs including the LANDSCAPE and NEST studies, which demonstrated its efficacy in rapidly reducing depressive symptoms. It is not currently approved for other forms of major depressive disorder, though research into broader applications is ongoing.

Pharmacology

Zuranolone functions as a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors. Its chemical structure is based on allopregnanolone, a naturally occurring neurosteroid metabolite of progesterone. By enhancing GABA-mediated inhibitory neurotransmission, zuranolone exerts rapid antidepressant and anxiolytic effects within the central nervous system. The drug is administered orally and exhibits nonlinear pharmacokinetics, with peak plasma concentrations reached within a few hours post-dose.

Adverse effects

Common adverse reactions associated with zuranolone include somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. Due to its central nervous system effects, the prescribing information includes a Boxed Warning regarding the potential for impaired driving and other activities requiring complete mental alertness. Patients are advised not to drive or operate heavy machinery for at least 12 hours after taking a dose. As with other GABAA receptor modulators, there is a potential for abuse and dependence, necessitating careful patient monitoring.

Clinical trials

The development of zuranolone was supported by several pivotal clinical trials. The ROBIN Study (Phase 3) and the SKYLARK Study (Phase 3) specifically evaluated its efficacy and safety in postpartum depression. In these randomized, double-blind, placebo-controlled trials, zuranolone met its primary endpoint, demonstrating a statistically significant reduction in depressive symptoms as measured by the Hamilton Rating Scale for Depression compared to placebo. Further research, such as the WATERFALL Study, investigated its potential in major depressive disorder, though with mixed results that led to a focused indication on postpartum depression.

Society and culture

The approval of zuranolone, co-developed by Sage Therapeutics and Biogen, was a significant event in psychopharmacology, highlighted by coverage in major journals like The New England Journal of Medicine. Its brand name, Zurzuvae, was approved alongside the FDA decision. The drug's introduction has sparked discussions about access, cost, and the need for novel treatments in perinatal psychiatry. The development pathway benefited from the prior regulatory experience with brexanolone, an intravenous therapy for postpartum depression also developed by Sage Therapeutics.

Chemistry

Zuranolone is a synthetic neuroactive steroid with the chemical name (3S,3aR,7S,7aR)-3-(2,4-difluorophenyl)-2-oxo-3,3a,4,5,6,7-hexahydro-2H-indazole-7-carboxamide. It is structurally analogous to the endogenous neurosteroid allopregnanolone. The compound is formulated as a hard gelatin capsule for oral administration. Its molecular formula is C15H15F2N3O2, and it has a molecular weight of 307.30 g/mol. The synthesis and development were conducted by researchers at Sage Therapeutics.

Category:Drugs Category:Antidepressants